<DOC>
	<DOCNO>NCT02666963</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacokinetic profile RTA 901 follow escalate single multiple oral dos RTA 901 healthy adult subject . This first-in-human , Phase 1 , single-center study consist single ascend dos ( SAD ) multiple ascend dos ( MAD ) conduct 2 part . Part 1 ( SAD ) study conduct approximately 56 healthy subject 7 group . Each group consist 8 subject randomize 3:1 ratio receive single dose RTA 901 placebo , respectively . Safety , tolerability , available pharmacokinetics Day 4 assess group prior dose escalation . Part 2 ( MAD ) study conduct approximately 30 healthy subject 3 group . Each group consist 10 subject randomize 4:1 ratio receive 14 daily dos RTA 901 placebo , respectively . Safety , tolerability , available pharmacokinetics Day 17 assess dose group prior dose escalation .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Pharmacokinetics Single Multiple Doses RTA 901 Healthy Adults</brief_title>
	<detailed_description />
	<criteria>Male female age 18 55 year , inclusive . Women must nonchildbearing potential may pregnant , lactate , breastfeed . Nonchildbearing potential define least one follow criterion : 1 . At least 2 year spontaneous amenorrhea ( attributable environmental pathological cause , e.g. , anorexia excessive exercise ) folliclestimulating hormone ( FSH ) postmenopausal range screening ; 2 . At least 3 month postsurgical bilateral oophorectomy tubal ligation ; 3 . Hysterectomy ( must great 5 year posthysterectomy due cancer ) ; Females must negative result pregnancy test perform : 1 . At screen base urine specimen obtain within 28 day prior initial study drug administration , 2 . Prior dose base serum sample obtain Day 1 . If male , subject must surgically sterile practice least 1 follow method contraception , initial study drug administration 90 day administration last dose study drug : 1 . Partner ( ) use IUD ; 2 . Partner ( ) use hormonal contraceptive ( oral , vaginal , parenteral , transdermal ) . 3 . Subject and/or partner ( ) use doublebarrier method ( condom , contraceptive sponge , diaphragm , vaginal ring spermicidal jelly cream ) ; 4 . Total abstinence sexual intercourse preferred life style subject ; periodic abstinence acceptable . If male , subject agree abstain sperm donation 90 day administration last dose study drug . Body Mass Index ( BMI ) ≥ 18 &lt; 32 kg/m2 , inclusive . A condition general good health , base upon result medical history , physical examination , vital sign , laboratory profile , 12lead electrocardiogram ( ECG ) , judge investigator . Must voluntarily sign date inform consent , approve Institutional Review Board ( IRB ) , prior initiation screen studyspecific procedure . History clinically significant drug allergy , include allergy component investigational product and/or clinically significant food allergy determine investigator ; History clinically significant drug allergy , include allergy component investigational product and/or clinically significant food allergy determine investigator ; Presence history significant cardiovascular , gastrointestinal , hepatic , renal , pulmonary , hematologic , endocrine , immunologic , dermatologic , neurologic , psychiatric disease , determine investigator ; Presence condition ( include surgery ) know interfere absorption , distribution , metabolism , excretion medicine . Requirement overthecounter and/or prescription medication , vitamin , and/or herbal supplement regular basis . Use medication ( overthecounter and/or prescription medication ) , vitamin , and/or herbal supplement , within 30day period prior study drug administration within 5 halflives ( know ) , whichever longer . Recent ( 6month ) history drug alcohol abuse . Positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) , HIV antibody ( HIV Ab ) screening . Donation loss 550 mL blood volume ( include plasmapheresis ) receipt transfusion blood product within 8 week prior study drug administration . Receipt investigational product within time period equal 10 halflives product , know , minimum 30 day prior study drug administration . Positive screen result drug abuse , alcohol , cotinine screen Day 1 . Consumption alcohol within 72 hour prior study drug administration . Consumption grapefruit , grapefruit product , star fruit , star fruit product , Seville oranges within 72hour period prior study drug administration . Use tobacco nicotinecontaining product within 6month period precede study drug administration . Current enrollment another clinical study . Previous enrollment study . Screening laboratory analysis show follow abnormal laboratory result : 1 . Alanine transaminase ( ALT ) level 1.2× upper limit normal ( ULN ) . 2 . Aspartate transaminase ( AST ) level 1.2× ULN . 3 . Any laboratory result outside laboratory normal reference range consider clinically significant investigator . Clinicallysignificant abnormal ECG ; ECG QTc use Fridericia 's correction formula ( QTcF ) &gt; 450 msec exclusionary . Consideration investigator , reason , subject unsuitable candidate receive RTA 901 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>RTA 901</keyword>
	<keyword>RTA 901 capsule</keyword>
</DOC>